Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

Author： Kozma Chris M.   Slaton Terra   Dirani Riad   Fastenau John   Gopal Srihari   Hough David  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.8, 2011-08, pp. : 1603-1611

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials

By Janicak Philip G.   Wu Jasmanda H.   Mao Lian  

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1807-1815

Informa Healthcare

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial

By Potvin Stéphane   Stip Emmanuel   Lipp Olivier   Élie Robert   Mancini-Marië Adham   Demers Marie-France   Roy Marc-André   Bouchard Roch-Hugo   Gendron Alain  

Current Medical Research and Opinion, Vol. 22, Iss. 7, 2006-07 ,pp. : 1277-1285

Informa Healthcare

Access to resources Recommend Favorite

The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 191, Iss. 2, 2018-02 ,pp. : 229-239

John Wiley & Sons Inc

Access to resources Recommend Favorite